The William Harvey Research Institute (WHRI) was founded in 1986 by the Nobel Laureate Sir John Vane, discoverer of the action of aspirin and prostacyclin. The goal of Sir John Vane was to create an international powerhouse in pharmacological research operating at the academic/industry interface.
Since 2000, as part of Barts and The London School of Medicine and Dentistry (SMD) and Queen Mary University of London, the WHRI and the SMD have gone from strength to strength. In the 2008 Research Assessment Exercise, the SMD was ranked overall 5th in the UK for world-leading or internationally excellent research. Over this same period, the School’s research spend increased from £18.7m to over £60m.
Our success includes the growth in depth and quality of our cardiovascular, inflammation and endocrine research programmes. We aim to combine talents from different disciplines, such as genomics, cell biology, pharmacology, with translational bench to patient studies and large-scale clinical trials, all with the ambition of therapeutic innovation.
We are currently the largest pharmacological research institute in the UK University sector and one of the largest in Europe. We have grown from 140 people, in 2002, to number, in 2018, over 530 clinicians and scientists from 45 countries.
- To lead world-class research in cardiovascular, inflammatory and endocrine diseases with the aim of discovering new mechanisms, validating targets and leading therapeutic innovation with translation into patient care.
- To provide the highest calibre teaching in pharmacology and safe prescribing.
- To be a leading training provider for UK and international postgraduate students and to develop young talented scientists in therapeutic innovation.
- To develop international partnerships with pharma and biotechs.